4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 9.4% – Time to Sell?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)’s share price fell 9.4% during mid-day trading on Friday . The stock traded as low as $11.67 and last traded at $11.6720. Approximately 165,120 shares traded hands during trading, a decline of 80% from the average daily volume of 815,943 shares. The stock had previously closed at $12.89.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. The Goldman Sachs Group set a $33.00 price objective on shares of 4D Molecular Therapeutics in a research report on Friday, May 8th. Chardan Capital restated a “buy” rating and set a $26.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, March 19th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Friday, March 20th. Royal Bank Of Canada increased their price target on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a research note on Thursday, March 19th. Finally, Wall Street Zen cut 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $29.88.

4D Molecular Therapeutics Stock Performance

The company has a market cap of $625.27 million, a price-to-earnings ratio of -4.64 and a beta of 2.70. The stock’s fifty day simple moving average is $10.14 and its two-hundred day simple moving average is $9.31.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The firm had revenue of $3.05 million for the quarter, compared to analyst estimates of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. Analysts predict that 4D Molecular Therapeutics, Inc. will post -4.14 EPS for the current fiscal year.

Insider Transactions at 4D Molecular Therapeutics

In other news, insider David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $10.47, for a total value of $1,201,390.62. Following the transaction, the insider directly owned 942,485 shares of the company’s stock, valued at $9,867,817.95. The trade was a 10.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Scott Bizily sold 9,810 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the sale, the insider owned 8,617 shares of the company’s stock, valued at $103,404. The trade was a 53.24% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 126,478 shares of company stock valued at $1,338,369. 7.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of FDMT. Janus Henderson Group PLC lifted its position in 4D Molecular Therapeutics by 164.4% during the fourth quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company’s stock valued at $34,726,000 after buying an additional 2,882,508 shares in the last quarter. State Street Corp increased its position in shares of 4D Molecular Therapeutics by 197.5% in the fourth quarter. State Street Corp now owns 2,688,880 shares of the company’s stock worth $20,167,000 after acquiring an additional 1,785,106 shares in the last quarter. RA Capital Management L.P. raised its stake in shares of 4D Molecular Therapeutics by 23.9% in the 4th quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock valued at $42,399,000 after acquiring an additional 1,090,000 shares during the period. Adage Capital Partners GP L.L.C. raised its stake in shares of 4D Molecular Therapeutics by 605.8% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,235,156 shares of the company’s stock valued at $9,264,000 after acquiring an additional 1,060,156 shares during the period. Finally, Evergreen Quality Fund GP Ltd. acquired a new position in shares of 4D Molecular Therapeutics during the 4th quarter valued at $7,136,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.